Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study
Hu, YX; Zhou, YL; Zhang, MM; Zhao, HL; Wei, GQ; Ge, WG; Cui, Q; Mu, QT; Chen, G; Han, L; Guo, TT; Cui, JZ; Jiang, XY; Zheng, XJ; Yu, SH; Li, XL; Zhang, XW; Chen, MX; Li, XJ; Gao, M; Wang, K; Zu, C; Zhang, H; He, XH; Wang, YB; Wang, DR; Ren, JT; Huang, H
Hu, YX; Wang, DR; Huang, H (通讯作者)，Zhejiang Univ, Affiliated Hosp 1, Sch Med, Bone Marrow Transplantat Ctr, Hangzhou, Zhejiang, Peoples R China.;Hu, YX; Wang, DR; Huang, H (通讯作者)，Zhejiang Univ, Liangzhu Lab, Med Ctr, Hangzhou, Zhejiang, Peoples R China.;Hu, YX; Wang, DR; Huang, H (通讯作者)，Zhejiang Univ, Inst Hematol, Hangzhou, Zhejiang, Peoples R China.;Hu, YX; Wang, DR; Huang, H (通讯作者)，Zhejiang Prov Engn Lab Stem Cell & Immun Therapy, Hangzhou, Zhejiang, Peoples R China.;Ren, JT (通讯作者)，Nanjing Bio
CELL RESEARCH, 2022; 32 (11): 995
